Most clients with DSM-5® diagnoses are being treated with a combination of psychological and pharmacological treatments. Newer drugs are being developed to treat mental disorders based on a better understanding of neurobiological contributions to mental disorders and the latest pharmacological research. To provide appropriate services, you are expected to have a thorough understanding of these common and complex issues. As a mental health professional, keeping up-to-date is essential.
This recording will update and increase your knowledge of:
Specifics of the pharmacological treatment and drugs of choice for Depressive, Bipolar, Schizophrenia Spectrum, Anxiety, OCD, Sleep-Wake, ADHD and Neurocognitive disorders will be presented. Unique to this recording is information on the common types of psychotherapeutic drugs and other drugs that are abused, and methods for prevention and early detection. Throughout the day, representative case studies will generate discussion and examination of the latest drug treatment for DSM-5® disorders.
You will leave this recording with knowledge and confidence regarding effective and safe application of pharmacological drugs.
This online program is worth 6.25 hours CPD.
| File type | File name | Number of pages | |
|---|---|---|---|
| Manual - Psychopharmacology for Mental Health Professionals (4.48 MB) | 65 Pages | Available after Purchase |
Alan S. Bloom, PhD, is Professor Emeritus of Pharmacology and Toxicology at the Medical College of Wisconsin where he taught psychopharmacology to medical students and neuroscience graduate students. He earned a joint PhD in psychology and pharmacology and consults regularly with psychiatrists and attorneys in drug abuse and other pharmacology related cases.
Dr. Bloom has conducted extensive research on the impact of drugs of abuse (marijuana, cocaine, etc.) on the brain through use of functional magnetic resonance imaging (fMRI). His studies have been funded by the NIH and other national organizations and reported in an extensive number of publications and presentations. Dr. Bloom has served on the NIDA Center grant review panel and is an appointed member of the Controlled Substance Board of the State of Wisconsin.
Dr. Bloom is a strong and experienced presenter providing lively, information-packed seminars. He encourages the active learning of participants through application of the material in case studies and problem-based learning. In 1997 he was elected to membership in the Medical College of Wisconsin Society of Teaching Scholars.
Speaker Disclosures:
Financial: Dr. Alan Bloom receives a speaking honorarium and recording royalties from PESI, Inc. Dr. Bloom has no relevant financial relationships with ineligible organizations.
Non-financial: Dr. Alan Bloom is the Vice Chair of the State of Wisconsin Controlled Substances Board.
Depressive Disorders
Schizophrenia Spectrum Disorders
Bipolar Disorders
Anxiety, Obsessive-Compulsive & Sleep-Wake Disorders
Attention-Deficit/Hyperactivity Disorder & Neurocognitive Disorders (Dementia)
Prescription Drug Abuse
| 5 |
|
| 4 |
|
| 3 |
|
| 2 |
|
| 1 |
|
Satisfaction Guarantee
Your satisfaction is our goal and our guarantee. Concerns should be addressed to info@pesi.co.uk or call 01235847393.
Please wait ...